601 related articles for article (PubMed ID: 27825616)
1. Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial.
Yoh K; Seto T; Satouchi M; Nishio M; Yamamoto N; Murakami H; Nogami N; Matsumoto S; Kohno T; Tsuta K; Tsuchihara K; Ishii G; Nomura S; Sato A; Ohtsu A; Ohe Y; Goto K
Lancet Respir Med; 2017 Jan; 5(1):42-50. PubMed ID: 27825616
[TBL] [Abstract][Full Text] [Related]
2. Final survival results for the LURET phase II study of vandetanib in previously treated patients with RET-rearranged advanced non-small cell lung cancer.
Yoh K; Seto T; Satouchi M; Nishio M; Yamamoto N; Murakami H; Nogami N; Nosaki K; Kohno T; Tsuta K; Nomura S; Ikeno T; Wakabayashi M; Sato A; Matsumoto S; Goto K
Lung Cancer; 2021 May; 155():40-45. PubMed ID: 33725547
[TBL] [Abstract][Full Text] [Related]
3. Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial.
Lee SH; Lee JK; Ahn MJ; Kim DW; Sun JM; Keam B; Kim TM; Heo DS; Ahn JS; Choi YL; Min HS; Jeon YK; Park K
Ann Oncol; 2017 Feb; 28(2):292-297. PubMed ID: 27803005
[TBL] [Abstract][Full Text] [Related]
4. A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies.
Platt A; Morten J; Ji Q; Elvin P; Womack C; Su X; Donald E; Gray N; Read J; Bigley G; Blockley L; Cresswell C; Dale A; Davies A; Zhang T; Fan S; Fu H; Gladwin A; Harrod G; Stevens J; Williams V; Ye Q; Zheng L; de Boer R; Herbst RS; Lee JS; Vasselli J
BMC Cancer; 2015 Mar; 15():171. PubMed ID: 25881079
[TBL] [Abstract][Full Text] [Related]
5. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study.
Gainor JF; Curigliano G; Kim DW; Lee DH; Besse B; Baik CS; Doebele RC; Cassier PA; Lopes G; Tan DSW; Garralda E; Paz-Ares LG; Cho BC; Gadgeel SM; Thomas M; Liu SV; Taylor MH; Mansfield AS; Zhu VW; Clifford C; Zhang H; Palmer M; Green J; Turner CD; Subbiah V
Lancet Oncol; 2021 Jul; 22(7):959-969. PubMed ID: 34118197
[TBL] [Abstract][Full Text] [Related]
6. Characteristics and outcomes of RET-rearranged Korean non-small cell lung cancer patients in real-world practice.
Lee J; Ku BM; Shim JH; La Choi Y; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Jpn J Clin Oncol; 2020 May; 50(5):594-601. PubMed ID: 32083304
[TBL] [Abstract][Full Text] [Related]
7. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.
Gettinger SN; Bazhenova LA; Langer CJ; Salgia R; Gold KA; Rosell R; Shaw AT; Weiss GJ; Tugnait M; Narasimhan NI; Dorer DJ; Kerstein D; Rivera VM; Clackson T; Haluska FG; Camidge DR
Lancet Oncol; 2016 Dec; 17(12):1683-1696. PubMed ID: 27836716
[TBL] [Abstract][Full Text] [Related]
8. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.
Wells SA; Gosnell JE; Gagel RF; Moley J; Pfister D; Sosa JA; Skinner M; Krebs A; Vasselli J; Schlumberger M
J Clin Oncol; 2010 Feb; 28(5):767-72. PubMed ID: 20065189
[TBL] [Abstract][Full Text] [Related]
9. Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study.
Ahn MJ; Kim DW; Cho BC; Kim SW; Lee JS; Ahn JS; Kim TM; Lin CC; Kim HR; John T; Kao S; Goldman JW; Su WC; Natale R; Rabbie S; Harrop B; Overend P; Yang Z; Yang JC
Lancet Respir Med; 2017 Nov; 5(11):891-902. PubMed ID: 29056570
[TBL] [Abstract][Full Text] [Related]
10. Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.
Gautschi O; Milia J; Filleron T; Wolf J; Carbone DP; Owen D; Camidge R; Narayanan V; Doebele RC; Besse B; Remon-Masip J; Janne PA; Awad MM; Peled N; Byoung CC; Karp DD; Van Den Heuvel M; Wakelee HA; Neal JW; Mok TSK; Yang JCH; Ou SI; Pall G; Froesch P; Zalcman G; Gandara DR; Riess JW; Velcheti V; Zeidler K; Diebold J; Früh M; Michels S; Monnet I; Popat S; Rosell R; Karachaliou N; Rothschild SI; Shih JY; Warth A; Muley T; Cabillic F; Mazières J; Drilon A
J Clin Oncol; 2017 May; 35(13):1403-1410. PubMed ID: 28447912
[TBL] [Abstract][Full Text] [Related]
11. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.
Seto T; Kato T; Nishio M; Goto K; Atagi S; Hosomi Y; Yamamoto N; Hida T; Maemondo M; Nakagawa K; Nagase S; Okamoto I; Yamanaka T; Tajima K; Harada R; Fukuoka M; Yamamoto N
Lancet Oncol; 2014 Oct; 15(11):1236-44. PubMed ID: 25175099
[TBL] [Abstract][Full Text] [Related]
12. Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial.
Drilon A; Rekhtman N; Arcila M; Wang L; Ni A; Albano M; Van Voorthuysen M; Somwar R; Smith RS; Montecalvo J; Plodkowski A; Ginsberg MS; Riely GJ; Rudin CM; Ladanyi M; Kris MG
Lancet Oncol; 2016 Dec; 17(12):1653-1660. PubMed ID: 27825636
[TBL] [Abstract][Full Text] [Related]
13. Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases.
Subbiah V; Berry J; Roxas M; Guha-Thakurta N; Subbiah IM; Ali SM; McMahon C; Miller V; Cascone T; Pai S; Tang Z; Heymach JV
Lung Cancer; 2015 Jul; 89(1):76-9. PubMed ID: 25982012
[TBL] [Abstract][Full Text] [Related]
14. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.
Wu YL; Cheng Y; Zhou J; Lu S; Zhang Y; Zhao J; Kim DW; Soo RA; Kim SW; Pan H; Chen YM; Chian CF; Liu X; Tan DSW; Bruns R; Straub J; Johne A; Scheele J; Park K; Yang JC;
Lancet Respir Med; 2020 Nov; 8(11):1132-1143. PubMed ID: 32479794
[TBL] [Abstract][Full Text] [Related]
15. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer.
Heymach JV; Johnson BE; Prager D; Csada E; Roubec J; Pesek M; Spásová I; Belani CP; Bodrogi I; Gadgeel S; Kennedy SJ; Hou J; Herbst RS
J Clin Oncol; 2007 Sep; 25(27):4270-7. PubMed ID: 17878479
[TBL] [Abstract][Full Text] [Related]
16. Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR).
Lee JS; Hirsh V; Park K; Qin S; Blajman CR; Perng RP; Chen YM; Emerson L; Langmuir P; Manegold C
J Clin Oncol; 2012 Apr; 30(10):1114-21. PubMed ID: 22370318
[TBL] [Abstract][Full Text] [Related]
17. Emergence of a RET V804M Gatekeeper Mutation During Treatment With Vandetanib in RET-Rearranged NSCLC.
Dagogo-Jack I; Stevens SE; Lin JJ; Nagy R; Ferris L; Shaw AT; Gainor JF
J Thorac Oncol; 2018 Nov; 13(11):e226-e227. PubMed ID: 30368414
[No Abstract] [Full Text] [Related]
18. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
Shaw AT; Felip E; Bauer TM; Besse B; Navarro A; Postel-Vinay S; Gainor JF; Johnson M; Dietrich J; James LP; Clancy JS; Chen J; Martini JF; Abbattista A; Solomon BJ
Lancet Oncol; 2017 Dec; 18(12):1590-1599. PubMed ID: 29074098
[TBL] [Abstract][Full Text] [Related]
19. Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial.
Neal JW; Dahlberg SE; Wakelee HA; Aisner SC; Bowden M; Huang Y; Carbone DP; Gerstner GJ; Lerner RE; Rubin JL; Owonikoko TK; Stella PJ; Steen PD; Khalid AA; Ramalingam SS;
Lancet Oncol; 2016 Dec; 17(12):1661-1671. PubMed ID: 27825638
[TBL] [Abstract][Full Text] [Related]
20. RET-rearranged non-small-cell lung cancer and therapeutic implications.
Loh Z; Mitchell P; John T; Arulananda S
Intern Med J; 2019 Dec; 49(12):1541-1545. PubMed ID: 31808254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]